4 results
To assess the effect of oral UT-15C with PAH-approved oral monotherapy compared to placebo with PAHapproved oral monotherapy on time to first clinical worsening event (adjudicated), as defined by at least one of the events listed below:- Death (all…
The central hypothesis of this project is that atorvastatin (added on standard antihypertensive treatment ARB) causes a substantial decrease in MSNA in hypertensive patients with CKD.
Primary Objective: To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.Secondary Objectives:1. To compare the efficacy of MEDI-551 versus placebo on the reduction of EDSS…
To provide UT-15C for eligible subjects who participated in study protocol TDE-PH-310